Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment DOI Open Access
Victoria Serhiyenko, A.A. Serhiyenko

World Journal of Diabetes, Journal Year: 2018, Volume and Issue: 9(1), P. 1 - 24

Published: Jan. 10, 2018

Cardiac autonomic neuropathy (CAN) is a serious com-plication of diabetes mellitus (DM) that strongly associated with approximately five-fold increased risk cardiovascular mortality.CAN manifests in spectrum things, ranging from resting tachycardia and fixed heart rate (HR) to development "silent" myocardial infarction.Clinical correlates or markers for CAN are age, DM duration, glycemic control, hypertension, dyslipidemia (DLP), other microvascular complications.Established factors poor control type 1 combination DLP, obesity, unsatisfactory 2 DM.Symptomatic manifestations include sinus tachycardia, exercise intolerance, orthostatic hypotension (OH), abnormal blood pressure (BP) regulation, dizziness, presyncope syncope, intraoperative instability, asymptomatic ischemia infarction.Methods assessment clinical practice symptoms signs, reflex tests based on HR BP, short-term electrocardiography (ECG), QT interval prolongation, variability (24 h, classic 24 h Holter ECG), ambulatory BP monitoring, turbulence, baroreflex sensitivity, muscle sympathetic nerve activity, catecholamine tests, imaging.Although it common complication, the significance has not been fully appreciated there no unified treatment algorithms today.Treatment early diagnosis, life style changes, optimization management factors.Pathogenetic includes: Balanced diet physical activity; control; DLP; antioxidants, first all α-lipoic acid (ALA), aldose reductase inhibitors, acetyl-L-carnitine; vitamins, fat-soluble vitamin B1; correction vascular endothelial dysfunction; prevention thrombosis; severe cases-treatment OH.The promising methods prescription prostacyclin analogues, thromboxane A2 blockers drugs contribute into strengthening and/or normalization Na + , K -ATPase (phosphodiesterase inhibitor), ALA, dihomo-γ-linolenic (DGLA), ω-3 polyunsaturated fatty acids (ω-3 PUFAs), simultaneous PUFAs DGLA, but future investigations

Language: Английский

Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary DOI Open Access

Alan J. Garber,

Yehuda Handelsman, George Grunberger

et al.

Endocrine Practice, Journal Year: 2020, Volume and Issue: 26(1), P. 107 - 139

Published: Jan. 1, 2020

Language: Английский

Citations

548
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial DOI
Marc S. Sabatine, Lawrence A. Leiter,

Stephen D. Wiviott

et al.

The Lancet Diabetes & Endocrinology, Journal Year: 2017, Volume and Issue: 5(12), P. 941 - 950

Published: Sept. 15, 2017

Language: Английский

Citations

538
The gut microbiome and metabolic syndrome DOI Open Access
Kruttika Dabke, Gustaf Hendrick, Suzanne Devkota

et al.

Journal of Clinical Investigation, Journal Year: 2019, Volume and Issue: 129(10), P. 4050 - 4057

Published: Sept. 30, 2019

The metabolic syndrome (MetS) is a constellation of risk factors that, if left untreated, will often progress to greater defects such as type 2 diabetes and nonalcoholic fatty liver disease. While these have been established for over 40 years, the definition MetS warrants reconsideration in light substantial data that emerged from studies gut microbiome. In this Review we present existing recent literature supports microbiome's potential influence on various MetS. interplay intestinal microbiota with host metabolism has shown be mediated by myriad factors, including defective barrier, bile acid metabolism, antibiotic use, pleiotropic effects microbially produced metabolites. These show events start gut, response external cues diet circadian disruption, far-reaching beyond gut.

Language: Английский

Citations

537
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline DOI Open Access

Derek LeRoith,

Geert Jan Biessels,

Susan S. Braithwaite

et al.

The Journal of Clinical Endocrinology & Metabolism, Journal Year: 2019, Volume and Issue: 104(5), P. 1520 - 1574

Published: March 23, 2019

The objective is to formulate clinical practice guidelines for the treatment of diabetes in older adults.

Language: Английский

Citations

453
The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk DOI Open Access
Pratik B. Sandesara, Salim S. Virani, Sergio Fazio

et al.

Endocrine Reviews, Journal Year: 2018, Volume and Issue: 40(2), P. 537 - 557

Published: Oct. 11, 2018

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death worldwide. Low-density lipoprotein cholesterol (LDL-C) is a well-established mediator atherosclerosis and key target for intervention primary secondary prevention ASCVD. However, despite substantial reduction in LDL-C, patients continue to have recurrent ASCVD events. Hypertriglyceridemia may be an important contributor this residual risk. Observational genetic epidemiological data strongly support causal role triglycerides (TGs) content within triglyceride-rich lipoproteins (TGRLs) and/or remnant (RC) development TGRLs are composed hepatically derived very low-density intestinally chylomicrons. RC all plasma TGs serve as surrogate measure RC. Although lifestyle modification cornerstone management hypertriglyceridemia, many novel drugs shown impressive efficacy lowering TG levels. Several ongoing, randomized controlled trials underway examine impact these agents on outcomes. In comprehensive review, we provide overview biology, epidemiology, genetics ASCVD; discuss current TG-lowering therapies under development.

Language: Английский

Citations

418
Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures – 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists DOI
Jeffrey I. Mechanick,

Caroline M. Apovian,

Stacy A. Brethauer

et al.

Surgery for Obesity and Related Diseases, Journal Year: 2019, Volume and Issue: 16(2), P. 175 - 247

Published: Nov. 3, 2019

Language: Английский

Citations

417
Clinical Practice Guidelines For The Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures – 2019 Update: Cosponsored By American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society For Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists DOI Open Access
Jeffrey I. Mechanick,

Caroline M. Apovian,

Stacy A. Brethauer

et al.

Endocrine Practice, Journal Year: 2019, Volume and Issue: 25, P. 1 - 75

Published: Nov. 4, 2019

Language: Английский

Citations

399
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities DOI Open Access
Craig A. Elmets,

Craig L. Leonardi,

Dawn Marie R. Davis

et al.

Journal of the American Academy of Dermatology, Journal Year: 2019, Volume and Issue: 80(4), P. 1073 - 1113

Published: Feb. 13, 2019

Language: Английский

Citations

378
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus DOI Open Access
Robert P. Giugliano, Christopher P. Cannon,

Michael A. Blazing

et al.

Circulation, Journal Year: 2017, Volume and Issue: 137(15), P. 1571 - 1582

Published: Dec. 20, 2017

Background: Ezetimibe, when added to simvastatin, reduces cardiovascular events after acute coronary syndrome. We explored outcomes stratified by diabetes mellitus (DM). Methods: In IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), 18 144 patients syndrome with low-density lipoprotein cholesterol 50 125 mg/dL were randomized 40 mg ezetimibe/simvastatin (E/S) or placebo/simvastatin. The primary composite end point was death, major events, and stroke. DM a prespecified subgroup. Results: 4933 (27%) more often older female, had prior myocardial infarction revascularization, presented frequently non-ST segment elevation compared without (each P <0.001). median admission lower among (89 versus 97 mg/dL, E/S achieved significantly time-weighted average placebo/simvastatin, irrespective (DM: 49 67 mg/dL; no DM: 55 71 both DM, reduced the 7-year Kaplan–Meier event rate 5.5% absolute (hazard ratio, 0.85; 95% confidence interval, 0.78-0.94); in difference 0.7% 0.98; 0.91–1.04; int =0.02). largest relative reductions (24%) ischemic stroke (39%). No differences safety treatment present regardless DM. When further age, ≥75 years age 20% reduction ( =0.91), whereas <75 greater benefit than those =0.011). TIMI (Thrombolysis Myocardial Infarction) Risk Score for Secondary Prevention, all demonstrated risk. contrast, high risk score experienced significant (18%) infarction, at low moderate addition ezetimibe simvastatin =0.034). Conclusions: IMPROVE-IT, adding statin enhanced high-risk Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00202878.

Language: Английский

Citations

367
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 DOI Open Access
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda

et al.

Diabetes Care, Journal Year: 2022, Volume and Issue: 46(Supplement_1), P. S158 - S190

Published: Dec. 12, 2022

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide components diabetes care, general treatment goals guidelines, tools evaluate quality care. Members ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating Standards annually, or more frequently as warranted. For detailed description standards, statements, reports, well evidence-grading system full list Committee members, please refer Introduction Methodology. Readers who wish comment on invited do so at professional.diabetes.org/SOC.

Language: Английский

Citations

344